CD8A and neoplasm: Despite the overall immunosuppressive role of Rapamycin, mTOR inhibition with Rapalogs has been shown to favor the expansion of CD8+ memory T cells [313] and to have a synergistic effect with different types of immunotherapies in some preclinical tumor models.